Ignite proteomics to present data on mhc-ii as a predictor of pembrolizumab response at nccn annual conference

Golden, co, feb. 24, 2025 (globe newswire) -- ignite proteomics llc, a subsidiary of imac holdings, inc. (nasdaq: back), today announced the presentation of new data demonstrating that mhc-ii protein expression is a superior predictor of response to pembrolizumab (keytruda®) compared to pd-l1 at the upcoming national comprehensive cancer network (nccn) annual conference. the study, conducted with i-spy 2 clinical trial results, evaluated five different pd-l1 antibodies – including the one most commonly used as a companion diagnostic – yet only mhc-ii expression showed a statistically significant correlation with patient outcomes.
BACK Ratings Summary
BACK Quant Ranking